China Approves Commercial BCI for Grasp
What happened
China approved its first commercial brain‑computer interface device that restores hand grasping for paralysis patients — a notable regulatory milestone for embodied AI and neuroprosthetics. The approval underscores accelerating commercialization of BCI applications in assistive robotics and medical devices reported.
Why it matters
Neuracle Medical Technology (also reported as Borui Kang Medical Technology) won market registration from China’s National Medical Products Administration on March 13, 2026, according to the regulator’s announcement. wincountry.com The product is registered under the name “Invasive Brain‑Computer Interface Hand Motor Function Compensation System,” and the clearance specifically targets adults aged 18–60 with quadriplegia caused by cervical spinal‑cord injury. yicaiglobal.com Regulatory filings and press reports describe the implant as a minimally invasive epidural device that sits on the brain’s surface and wirelessly transmits decoded motor intent to a wearable pneumatic glove. news.cgtn.com Company trial data and coverage in Bloomberg and other outlets state patients in clinical studies achieved measurable gains in grasping and the ability to hold objects, with the system demonstrated on tasks such as drinking from a cup. bloomberg.com Chinese media and analysts flagged the approval as a world‑first commercial authorisation for an invasive BCI and contrasted it with U.S. rivals like Neuralink, which remained in clinical trial stages as of March 2026. wincountry.com Reports indicate the NMPA cleared the device via an innovative‑product registration pathway, giving Neuracle a formal route to hospital deployment and establishing a regulatory precedent for implant‑to‑actuator systems that pair cortical decoding with robotic or assistive wearables. yicaiglobal.com
Key numbers
- Neuracle Medical Technology (also reported as Borui Kang Medical Technology) won market registration from China’s National Medical Products Administration on March 13, 2026, according to the regulator’s announcement.
- wincountry.com The product is registered under the name “Invasive Brain‑Computer Interface Hand Motor Function Compensation System,” and the clearance specifically targets adults aged 18–60 with quadriplegia caused by cervical spinal‑cord injury.
- rivals like Neuralink, which remained in clinical trial stages as of March 2026.
What happens next
- wincountry.com The product is registered under the name “Invasive Brain‑Computer Interface Hand Motor Function Compensation System,” and the clearance specifically targets adults aged 18–60 with quadriplegia caused by cervical spinal‑cord injury.
Quick answers
What happened in China Approves Commercial BCI for Grasp?
China approved its first commercial brain‑computer interface device that restores hand grasping for paralysis patients — a notable regulatory milestone for embodied AI and neuroprosthetics. The approval underscores accelerating commercialization of BCI applications in assistive robotics and medical devices reported.
Why does China Approves Commercial BCI for Grasp matter?
Neuracle Medical Technology (also reported as Borui Kang Medical Technology) won market registration from China’s National Medical Products Administration on March 13, 2026, according to the regulator’s announcement. wincountry.com The product is registered under the name “Invasive Brain‑Computer Interface Hand Motor Function Compensation System,” and the clearance specifically targets adults aged 18–60 with quadriplegia caused by cervical spinal‑cord injury. yicaiglobal.com Regulatory filings and press reports describe the implant as a minimally invasive epidural device that sits on the brain’s surface and wirelessly transmits decoded motor intent to a wearable pneumatic glove. news.cgtn.com Company trial data and coverage in Bloomberg and other outlets state patients in clinical studies achieved measurable gains in grasping and the ability to hold objects, with the system demonstrated on tasks such as drinking from a cup. bloomberg.com Chinese media and analysts flagged the approval as a world‑first commercial authorisation for an invasive BCI and contrasted it with U.S. rivals like Neuralink, which remained in clinical trial stages as of March 2026. wincountry.com Reports indicate the NMPA cleared the device via an innovative‑product registration pathway, giving Neuracle a formal route to hospital deployment and establishing a regulatory precedent for implant‑to‑actuator systems that pair cortical decoding with robotic or assistive wearables. yicaiglobal.com
